Identifying biomarkers is vital for interstitial lung disease (ILD) management and prognostication. While anti-Ro52 antibodies are frequently detected in autoimmune diseases, their significance in ILD remains unclear. What is the prognostic significance of anti-Ro52 positivity in patients with ILD? This retrospective cohort study used an ILD registry of patients seen at an academic tertiary hospital's ILD clinic between 2015 and 2024. All patients diagnosed with ILD and tested for anti-Ro52 antibody status were divided into anti-Ro52 positive (Anti-Ro52+) and negative (Anti-Ro52-) groups. The primary outcome was ILD progression or all-cause death. ILD progression was defined as any of the following: hospitalization due to ILD; absolute decline in forced vital capacity percent of predicted value ≥10% from baseline; or lung transplantation. Kaplan-Meier method and Cox proportional hazards regression model were used for survival analysis. Of 1,026 patients tested for the anti-Ro52 antibody (median age: 70 years; 52% male), 154 (15%) were Anti-Ro52+. Underlying ILD subtypes were as follows: interstitial pneumonia with autoimmune features (IPAF) (n = 489, 48%), connective tissue disease-ILD (n = 132, 13%), idiopathic pulmonary fibrosis (n = 103, 10%), hypersensitivity pneumonitis (n = 61, 6%), and other idiopathic ILD (n = 241, 24%). The Anti-Ro52+ group was younger (median age 67 vs. 70 years), was more likely to have CTD (28% vs. 10%) and more frequently had a copositive myositis-specific antibody (29% vs. 16%). After a median follow-up of 25.6 months, anti-Ro52+ subjects had a higher risk of ILD progression or death (hazard ratio 2.10; 95% CI, 1.61-2.73; P<0.001) and had a higher risk of lung transplant or death (hazard ratio 1.61; 95% CI, 1.11-2.35; P=0.014) on multivariable analysis. Anti-Ro52 seropositive ILD is associated with significantly worse progression-free and transplant-free survival and may inform disease prognostication and monitoring.
Current guidelines define progressive pulmonary fibrosis (PPF) as the presence of at least two of the following three changes within 12 months: worsening symptoms, lung function decline, or new/extending radiographic abnormalities [1, 2]. However, limiting assessment to subsequent progression may miss high-risk patients: those presenting with severely impaired lung function may meet none of the criteria if later tests remain unchanged, delaying therapy initiation and close monitoring. Therefore, we examined whether baseline forced vital capacity (FVC) was associated with an increased risk of lung transplantation or death in non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung disease (ILD) patients whose FVC declined by <5 percentage points predicted during the first year after diagnosis.
Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD), yet data on screening in heterogenous ILD populations are limited. We evaluated whether routinely measured pulmonary function test (PFT) parameters identify individuals with intermediate‐to‐high echocardiographic risk of PH. 432 ILD patients met inclusion criteria with an echocardiogram reporting peak tricuspid regurgitant velocity (TRV) and a PFT reporting diffusion impairment (DLCO) within 1 year (median interval, 39 days). Of these, 126 underwent right heart catheterization (RHC). Age‐ and sex‐ adjusted logistic regression assessed associations between %predicted forced vital capacity (FVC), %predicted DLCO, and FVC/DLCO ratio with intermediate‐to‐high echocardiographic PH probability (TRV > 2.8 m/s). Receiver operating characteristic curves evaluated diagnostic performance. The cohort included 28% systemic autoimmune rheumatic disease‐associated ILD, 27% interstitial pneumonia with autoimmune features, and 6% idiopathic pulmonary fibrosis, with a mean age of 72% and 54% female. Lower FVC and DLCO were associated with higher odds of echocardiographic PH (OR 1.35, 95%CI 1.21–1.50; OR 1.50, 95%CI 1.36–1.73) and increases in FVC/DLCO ratio similarly predicted risk (OR 1.83, 95%CI 1.44–2.32). DLCO had the highest predictive ability (AUC 0.74, 95%CI 0.69–0.79) with an optimal cut‐off of 42% (sensitivity 67%, specificity 74%). In patients who underwent RHC, TRV > 2.8 m/s correlated with mean pulmonary artery pressure (r = 0.55, 95%CI 0.42–0.66) and tripled the odds of confirmed PH (OR 3.75, 95%CI 2.25–6.24). In sum, severe diffusion impairment, regardless of fibrosis extent, may detect patients with ILD who warrant echocardiographic screening, specialty PH referral, and consideration of RHC.